Skip to search formSkip to main contentSkip to account menu

Gallium Ga 68 OPS202

Known as: 68Ga-OPS202 
A radioconjugate consisting of the somatostatin antagonistic peptide OPS202 that is labeled with the positron-emitting radionuclide gallium Ga 68… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Somatostatin Receptor Antagonists for Imaging and Therapy
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An… 
Highly Cited
2017
Highly Cited
2017
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastroenteropancreatic neuroendocrine tumors… 
Highly Cited
2017
Highly Cited
2017
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Preclinical and preliminary clinical evidence indicates that radiolabeled somatostatin (sst) receptor antagonists perform better… 
2017
2017
Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201.
4094Background: Radiolabeled somatostatin receptor 2 (sstr2) antagonists have shown higher tumor uptake and tumor-to-organ ratios… 
2016
2016
PET/CT with the somatostatin receptor antagonist 68Ga-OPS202 is twice as accurate as with the agonist 68Ga-DOTATOC for detecting liver metastases: Results of a phase 1/2 study in…
2015
2015
First clinical data on 68Ga-labeled somatostatin receptor antagonists: a phase I/II study comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)